Compare BridgeBio Pharma Inc (BBIO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wendys Co — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Wendys Co trades at $7.53 (market cap $1.39B). The key difference: BridgeBio Pharma Inc is far larger — about 11.9× Wendys Co's market cap, and Wendys Co pays a 3.84% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WEN | |
|---|---|---|
Market Cap | $16.61B | $1.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $10.68 |
52-Week Low | $47.29 | $6.17 |
Enterprise Value | $18.16B | $5.12B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Wendy's stock (WEN) trades at $7.69, up 4.06% in the last session, with a bullish technical signal from moving averages and a consensus price target of $9.33. Recent Q2 2026 EPS beat estimates at $0.18, but revenue trends show stagnation near $2.2B, with net income declining to $165M in 2025. The company faces headwinds from a dividend cut and lost market share to Burger King, as new leadership pursues a turnaround plan amid weak U.S. traffic.
The outlook is cautious; valuation ratios like P/E of 11.67 and P/S of 0.67 suggest undervaluation, but high debt and competitive pressures pose risks. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty over the turnaround's success. Near-term performance hinges on execution of strategic initiatives to revive sales and margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
